April 24, 2017 / 11:20 PM / 8 months ago

Business Watch: Drugmakers on the hunt

NASH drives deal making

A researcher prepares medicine at a laboratory in Nanjing University in Nanjing, Jiangsu province, China, in this April 29, 2011 file photo. China, already a global powerhouse in high-tech areas from solar panels to bullet trains, is turning its industrial might to the challenge of making more of its own drugs for a vast and ageing population. REUTERS/Aly Song/Files

The term Non-Alcoholic Steatohepatitis might sound obscure to most, but it stands for a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020. Big pharma sees the disease, abbreviated NASH, as an enormous new market for future profit that will accelerate a wave of deal making.

Today’s earnings:


Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below